• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CVS Health Corporation

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CVS alert in real time by email
    SC 13G 1 d793980dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 0 )*

     

     

    CVS HEALTH CORPORATION

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    126650100

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    PAGE 1 OF 5 PAGES


    CUSIP NO. 126650100    13G    PAGE 2 OF 5 PAGES

     

     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Dodge & Cox   94-1441976

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     N/A

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     California - U.S.A.

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     59,793,915

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     63,030,690

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     63,030,690

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     N/A

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.0%

    12  

     TYPE OF REPORTING PERSON*

     

     IA

     

    PAGE 2 OF 5 PAGES


    Item 1(a)

    Name of Issuer:

    CVS HEALTH CORPORATION

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    One CVS Drive

    Woonsocket, Rhode Island 02895

     

    Item 2(a)

    Name of Person Filing:

    Dodge & Cox

     

    Item 2(b)

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2(c)

    Citizenship:

    California - U.S.A.

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock

     

    Item 2(e)

    CUSIP Number:

    126650100

     

    Item 3

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

      (e)

    ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    63,030,690

     

      (b)

    Percent of Class:

    5.0%

     

    PAGE 3 OF 5 PAGES


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    59,793,915

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of: 63,030,690

     

      (iv)

    shared power to dispose or to direct the disposition of: 0

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, CVS HEALTH CORPORATION.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

     

    PAGE 4 OF 5 PAGES


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2024

     

    DODGE & COX
    By:  

    /S/ Katherine M. Primas

    Name:   Katherine M. Primas
    Title:   Chief Compliance Officer

     

    PAGE 5 OF 5 PAGES

    Get the next $CVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS

    DatePrice TargetRatingAnalyst
    8/18/2025$79.00Neutral → Buy
    UBS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    1/30/2025Hold → Buy
    Edward Jones
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    11/18/2024$60.00 → $66.00Equal Weight → Overweight
    Wells Fargo
    10/10/2024$63.00 → $82.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    2/19/25 12:35:35 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Ludwig Edward J bought $53,879 worth of shares (1,000 units at $53.88), increasing direct ownership by 5% to 21,630 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    5/2/24 4:31:44 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Health Foundation awards $1 Million in Hometown Fund grants to boost local impact in Hartford

    Grants will support local nonprofits improving health outcomes across the Greater Hartford area HARTFORD, Conn., Sept. 10, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) Foundation announced today that it is awarding $1 million in general operating grants through its Hometown Fund to 20 organizations surrounding the Hartford area. These organizations are committed to making health care more accessible and focusing on services that contribute to a healthier community, such as nutritious food, supportive housing and educational resources. "We created the Hometown Fund to support or

    9/10/25 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Updated flu vaccinations now available at CVS Pharmacy® and MinuteClinic®

    CVS Health® survey finds more than 60 percent of consumers say they are likely to get a flu shot this season Enhanced flu testing and treatment offerings are also available in select CVS Pharmacy locations across 38 states WOONSOCKET, R.I., Sept. 3, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that updated 2025-2026 flu vaccines are available at CVS Pharmacy® and MinuteClinic® locations nationwide. According to the Centers for Disease Control and Prevention (CDC), annual flu vaccination is the best way to help reduce the risk of contracting the flu and its potentially serious complications. Patients interested in getting a flu vaccine can quickly and easily make vaccination a

    9/3/25 8:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

    Financial Highlights Second quarter total revenues increased to $98.9 billion, up 8.4% compared to prior yearSecond quarter GAAP diluted EPS of $0.80 and Adjusted EPS of $1.81Generated year-to-date cash flow from operations of $6.5 billionOperational Highlights Aetna® delivers distinctive advances in care navigationCVS Pharmacy® agreed to acquire certain prescription files and store locations from Rite AidCVS Caremark® demonstrates market-leading innovation in strong renewal and sales season2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $3.84 to $3.94 from $4.23 to $4.43Raised Adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20Raised cash flow from operation

    7/31/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    SEC Filings

    View All

    SEC Form 144 filed by CVS Health Corporation

    144 - CVS HEALTH Corp (0000064803) (Subject)

    8/19/25 6:57:22 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    8/15/25 4:10:49 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 424B3 filed by CVS Health Corporation

    424B3 - CVS HEALTH Corp (0000064803) (Filer)

    8/11/25 8:14:25 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVS Health upgraded by UBS with a new price target

    UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00

    8/18/25 8:45:28 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded CVS Health from Neutral to Outperform and set a new price target of $82.00

    8/14/25 8:02:24 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded CVS Health from Market Perform to Outperform and set a new price target of $75.00 from $55.00 previously

    2/13/25 7:04:02 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Group President Shah Prem S covered exercise/tax liability with 6,995 shares, decreasing direct ownership by 10% to 60,632 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    9/2/25 4:42:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief Exp & Tech Officer Mandadi Tilak covered exercise/tax liability with 12,834 shares, decreasing direct ownership by 17% to 63,952 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    9/2/25 4:40:46 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Finucane Anne A. sold $532,650 worth of shares (7,500 units at $71.02) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    8/29/25 4:29:02 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

    WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

    4/8/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Foundation helps address barriers to care and provides resources for individuals with chronic health conditions in Hartford

    Foundation announces $2 million in new Health Zones funding to support at-risk populations WOONSOCKET, R.I., March 6, 2025 /PRNewswire/ -- The CVS Health® Foundation today announced $2 million in new Health Zones funding to support the Hispanic Health Council's Family Wellness Center and its agency partners, all located in Hartford, Connecticut. This funding will help address critical gaps in the health care and social system for individuals with chronic health conditions by increasing access to comprehensive health care services and resources. "A variety of interconnected fac

    3/6/25 8:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health announces Pharmacy and Consumer Wellness leadership appointments

    WOONSOCKET, R.I., Dec. 3, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Len Shankman will be president, Pharmacy and Consumer Wellness (PCW), reporting to Prem Shah, group president, CVS Health. In addition, the company announced the appointment of Lucille Accetta, RPh, MPH, MBA as chief pharmacy officer, also reporting to Shah. Both appointments are effective immediately. As president, Pharmacy and Consumer Wellness, Shankman will oversee the front store and retail pharmacy businesses across the company's more than 9,000 CVS Pharmacy locations. In his new

    12/3/24 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Financials

    Live finance-specific insights

    View All

    CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

    Financial Highlights Second quarter total revenues increased to $98.9 billion, up 8.4% compared to prior yearSecond quarter GAAP diluted EPS of $0.80 and Adjusted EPS of $1.81Generated year-to-date cash flow from operations of $6.5 billionOperational Highlights Aetna® delivers distinctive advances in care navigationCVS Pharmacy® agreed to acquire certain prescription files and store locations from Rite AidCVS Caremark® demonstrates market-leading innovation in strong renewal and sales season2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $3.84 to $3.94 from $4.23 to $4.43Raised Adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20Raised cash flow from operation

    7/31/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., July 7, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on August 1, 2025, to holders of record on July 22, 2025. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of March 31, 2025, the Company had more than 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care me

    7/7/25 9:39:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health to hold second quarter 2025 earnings conference call

    WOONSOCKET, R.I., June 30, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Thursday, July 31st, 2025, at 8:00 a.m. ET to discuss second quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of March 31, 2025, th

    6/30/25 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/9/23 11:16:32 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples